(Q45360538)

13 December 2017

title

Long-term effect of lamivudine treatment on the incidence of hepatocellular carcinoma in patients with hepatitis B virus infection (English)

1 reference

13 December 2017

1 reference

ChEBI release 2020-05-28

1 reference

hepatocellular carcinoma

1 reference

Mika Kurokawa

1

1 reference

13 December 2017

Naoki Hiramatsu

2

1 reference

13 December 2017

Tsugiko Oze

3

1 reference

13 December 2017

Takayuki Yakushijin

4

1 reference

13 December 2017

Masanori Miyazaki

5

1 reference

13 December 2017

Atsushi Hosui

6

1 reference

13 December 2017

Takuya Miyagi

7

1 reference

13 December 2017

Yuichi Yoshida

8

1 reference

13 December 2017

Hisashi Ishida

9

1 reference

13 December 2017

Tomohide Tatsumi

10

1 reference

13 December 2017

Shinichi Kiso

11

1 reference

13 December 2017

Tatsuya Kanto

12

1 reference

13 December 2017

Akinori Kasahara

13

1 reference

13 December 2017

Sadaharu Iio

14

1 reference

13 December 2017

Yoshinori Doi

15

1 reference

13 December 2017

Akira Yamada

16

1 reference

13 December 2017

Masahide Oshita

17

1 reference

13 December 2017

Akira Kaneko

18

1 reference

13 December 2017

Kiyoshi Mochizuki

19

1 reference

13 December 2017

Hideki Hagiwara

20

1 reference

13 December 2017

Eiji Mita

21

1 reference

13 December 2017

Toshifumi Ito

22

1 reference

13 December 2017

Yoshiaki Inui

23

1 reference

13 December 2017

Kazuhiro Katayama

24

1 reference

13 December 2017

Harumasa Yoshihara

25

1 reference

13 December 2017

Yasuharu Imai

26

1 reference

13 December 2017

Eijirou Hayashi

27

1 reference

13 December 2017

Norio Hayashi

28

1 reference

13 December 2017

Tetsuo Takehara

29

1 reference

13 December 2017

publication date

11 January 2012

1 reference

Journal of Gastroenterology

13 December 2017

published in

1 reference

13 December 2017

volume

47

1 reference

13 December 2017

issue

5

1 reference

13 December 2017

page(s)

577-585

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

13 December 2017

1 reference

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Hepatitis B virus. The major etiology of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Epidemiology of hepatocellular carcinoma in Japan and Korea. A review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Implication of frequent local ablation therapy for intrahepatic recurrence in prolonged survival of patients with hepatocellular carcinoma undergoing hepatic resection: an analysis of 610 patients over 16 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

A long-term follow-up and management study of hepatocellular carcinoma patients surviving for 10 years or longer after curative hepatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Hepatitis B virus-related cirrhosis: natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Natural history of chronic hepatitis B virus infection and long-term outcome under treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-011-0522-7

Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study

21 January 2018

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

1 reference

12 December 2020

Epidemiological characteristics and risk factors of hepatocellular carcinoma

1 reference

12 December 2020

The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 years observation

1 reference

12 December 2020

Hepatitis C virus and hepatocellular carcinoma

1 reference

12 December 2020

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

12 December 2020

10.1007/S00535-011-0522-7

Identifiers

DOI

1 reference

13 December 2017

1 reference